What does this research mean for the field?

While botulinum toxin-A injection is an effective first-line treatment for retrograde cricopharyngeal dysfunction, the field currently lacks standardized diagnostic criteria, uniform outcome measures, and evidence-based management strategies for treatment failures. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To synthesize the evidence on diagnosis, treatment approaches, and treatment failures in retrograde cricopharyngeal dysfunction over the past five years.

August 22, 2026Current Opinion in Otolaryngology & Head & Neck Surgery

Retrograde cricopharyngeal dysfunction: 5 years on, what is the evidence, who are the failures?

View Full Paper

Ask AI

Bookmark

Authors

TCTrina Kailin Chia ZLZhou Hao Leong

Discussion

Member takes

Overview

Narrative review reveals high success for botulinum toxin injection in retrograde cricopharyngeal dysfunction, highlighting a lack of standardized diagnostic criteria and salvage protocols.

Key Points

To synthesize the evidence on diagnosis, treatment approaches, and treatment failures in retrograde cricopharyngeal dysfunction over the past five years.
Reviewed diagnostic modalities, including high-resolution impedance manometry, for identifying pathophysiological thresholds.
Assessed delivery routes (transoral in operating theatre vs. percutaneous in-office) and efficacy outcomes of botulinum toxin-A (BoNT-A) injections into the cricopharyngeus muscle.
Evaluated current management strategies for treatment failure, including repeat injection, dose escalation, and surgical salvage.
First-line BoNT-A injection achieves high reported success rates via both transoral and percutaneous routes, though outcome definitions vary widely across studies.
High-resolution impedance manometry provides pathophysiological insight into dysfunction but lacks normative diagnostic cutoffs.
Data evaluating strategies for non-responders—including repeat injections and surgical salvage—remain sparse and largely anecdotal.

Cite This Study

Chia et al. (2026) studied this question.

synapsesocial.com/papers/6a895effca7ade938187d449 https://doi.org/10.1097/moo.0000000000001153

View Full Paper

Ask AI

Bookmark

August 22, 2026Current Opinion in Otolaryngology & Head & Neck Surgery

Retrograde cricopharyngeal dysfunction: 5 years on, what is the evidence, who are the failures?

View Full Paper

Ask AI

Bookmark

Authors

TCTrina Kailin Chia ZLZhou Hao Leong

Discussion

Member takes

Overview

Narrative review reveals high success for botulinum toxin injection in retrograde cricopharyngeal dysfunction, highlighting a lack of standardized diagnostic criteria and salvage protocols.

Key Points

To synthesize the evidence on diagnosis, treatment approaches, and treatment failures in retrograde cricopharyngeal dysfunction over the past five years.
Reviewed diagnostic modalities, including high-resolution impedance manometry, for identifying pathophysiological thresholds.
Assessed delivery routes (transoral in operating theatre vs. percutaneous in-office) and efficacy outcomes of botulinum toxin-A (BoNT-A) injections into the cricopharyngeus muscle.
Evaluated current management strategies for treatment failure, including repeat injection, dose escalation, and surgical salvage.
First-line BoNT-A injection achieves high reported success rates via both transoral and percutaneous routes, though outcome definitions vary widely across studies.
High-resolution impedance manometry provides pathophysiological insight into dysfunction but lacks normative diagnostic cutoffs.
Data evaluating strategies for non-responders—including repeat injections and surgical salvage—remain sparse and largely anecdotal.

Cite This Study

Chia et al. (2026) studied this question.

synapsesocial.com/papers/6a895effca7ade938187d449 https://doi.org/10.1097/moo.0000000000001153

View Full Paper

Ask AI

Bookmark